SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs latest Phase 3 breast-cancer results are drawing attention: the drug met its primary endpoint but delivered only a modest benefit versus chemotherapy, with higher lung-inflammation rates. Traders are debating whether this and an earlier cancer-trial setback signal broader pipeline weakness or are outweighed by other oncology programs and an upcoming pipeline update.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report and disclosure that the SEC closed its investigation without recommending enforcement action drove a sharp rally, with traders also pointing to record sales volumes. The move has fueled short-squeeze and momentum talk, while bears argue that an EPS miss, declining per-car margins and the end of numerical guidance undermine the growth story.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens run to recent highs has traders focused on its upcoming quarterly results, with options activity drawing attention; some view put buying as protection ahead of the report rather than a bearish bet. Optimism around the companys recent positive IMDELLTRA lung-cancer trial results also supports the pipeline discussion.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook fueled a sharp rally, with traders betting that AI-agent adoption will lift demand for identity security. The bullish AI-security thesis is being weighed against concerns that the stocks run has stretched its valuation, prompting profit-taking and calls for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut

Stryker shares plunge 11.8% after Q3 earnings and sales miss estimates, prompting a 2026 outlook cut amid weak joint procedures and execution challenges.

Cencora Gears Up to Report Q4 Results: How to Play the Stock?

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.

STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?

STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.

West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised

WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.

BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?

BrightSpring gears up for Q3 earnings, with strong Specialty, Infusion and Provider Services growth expected to offset IRA headwinds. Can it beat estimates?

Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?

ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) delivered earnings and revenue surprises of +4.00% and -0.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Waters Gears Up to Report Q3 Results: How to Play the Stock?

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$197.88
Prev Close	$198.34
Open	$199.77
Dividend Yield	2.22%
50-Day Moving Average	$186.60
Beta	0.44
Avg. Volume	1.8M
PE Ratio	59.69

52-Week High	$200.47
52-Week Low	$127.54
Market Capitalization	$53.9B
EPS (Annual)	$5.82
Price to Book	2.21
Revenue Per Employee	$303,333.33

Feed

News

Sentiment

Earnings

Fundamentals

Info

BDX Fundamentals